The effect of trimetazidine on reperfusion arrhythmias in acute myocardial infarction.
The study aims to evaluate the effect of trimetazidine in reducing reperfusion arrhythmias in patients with acute myocardial infarction after successful thrombolysis. A total of 169 patients were included in the study, 83 of whom received trimetazidine orally at an initial dose of 60 mg followed by 20 mg tid for 5 days. These patients formed the study group (group T) while the remaining 86, the control group (group C). Successful thrombolysis by clinical and electrocardiographic criteria was observed in 53 patients of group T and in 55 patients of group C. Reperfusion arrhythmias were observed in 16 patients in group T (30.1%) and in 31 in group C (56.3%). This difference was statistically significant. Serious ventricular arrhythmias (sustained ventricular tachycardia, ventricular fibrillation) were observed in 1 patient of group T (1.8%) and in 6 patients of group C (10.9%). This difference was also statistically significant. It is concluded that trimetazidine administration can reduce the rate of reperfusion arrhythmias. This conclusion should be confirmed by larger clinical trials in order to give to the clinical results a stronger statistical power.